Autolus Therapeutics (NASDAQ:AUTL) Price Target Raised to $11.00 at Needham & Company LLC

Autolus Therapeutics (NASDAQ:AUTL) had its price target lifted by Needham & Company LLC from $10.00 to $11.00 in a research note released on Monday,Benzinga reports. They currently have a buy rating on the stock.

AUTL has been the subject of a number of other research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Autolus Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen downgraded shares of Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, November 15th. Finally, William Blair reissued an “outperform” rating on shares of Autolus Therapeutics in a research note on Wednesday, September 24th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $8.67.

Autolus Therapeutics Stock Up 12.0%

Shares of NASDAQ AUTL opened at $1.87 on Monday. The company has a market cap of $497.68 million, a P/E ratio of -2.25 and a beta of 2.01. Autolus Therapeutics has a 52 week low of $1.11 and a 52 week high of $2.80. The business has a 50-day simple moving average of $1.49 and a two-hundred day simple moving average of $1.78.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.07). Autolus Therapeutics had a negative net margin of 439.69% and a negative return on equity of 63.76%. The firm had revenue of $21.19 million during the quarter, compared to the consensus estimate of $21.08 million. Equities research analysts anticipate that Autolus Therapeutics will post -0.94 EPS for the current year.

Hedge Funds Weigh In On Autolus Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Invesco Ltd. increased its holdings in Autolus Therapeutics by 53.3% during the 1st quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock valued at $51,000 after purchasing an additional 11,381 shares during the period. Vident Advisory LLC bought a new stake in shares of Autolus Therapeutics in the 1st quarter worth approximately $241,000. Jane Street Group LLC increased its stake in shares of Autolus Therapeutics by 809.4% during the first quarter. Jane Street Group LLC now owns 102,493 shares of the company’s stock valued at $159,000 after buying an additional 91,222 shares during the period. Atle Fund Management AB increased its stake in shares of Autolus Therapeutics by 130.5% during the second quarter. Atle Fund Management AB now owns 1,105,461 shares of the company’s stock valued at $2,520,000 after buying an additional 625,817 shares during the period. Finally, Avanza Fonder AB raised its holdings in shares of Autolus Therapeutics by 151.6% during the second quarter. Avanza Fonder AB now owns 53,522 shares of the company’s stock valued at $122,000 after acquiring an additional 32,246 shares in the last quarter. Institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.